LCA 0061
Alternative Names: LCA-0061Latest Information Update: 31 Mar 2025
At a glance
- Originator Lycia Therapeutics
- Class Antiallergics; Skin disorder therapies
- Mechanism of Action Immunoglobulin E inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Allergic asthma; Chronic urticaria; Food hypersensitivity
Most Recent Events
- 11 Feb 2025 Preclinical trials in Allergic asthma in USA (unspecified route) prior to February 2025 (Lycia Therapeutics Pipeline, February 2025)
- 11 Feb 2025 Preclinical trials in Chronic-urticaria in USA (unspecified route) prior to February 2025 (Lycia Therapeutics Pipeline, February 2025)
- 11 Feb 2025 Preclinical trials in Food hypersensitivity in USA (unspecified route) prior to February 2025 (Lycia Therapeutics Pipeline, February 2025)